Compare CHOW & RGNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHOW | RGNT |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 14.3M |
| IPO Year | 2024 | 2022 |
| Metric | CHOW | RGNT |
|---|---|---|
| Price | $0.30 | $1.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.5M | 46.6K |
| Earning Date | 05-15-2026 | 09-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $1.23 |
| 52 Week High | $12.05 | $15.50 |
| Indicator | CHOW | RGNT |
|---|---|---|
| Relative Strength Index (RSI) | 34.57 | 38.48 |
| Support Level | $0.36 | $1.23 |
| Resistance Level | $0.47 | $2.48 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 1.69 | 23.46 |
ChowChow Cloud International Holdings Ltd provides one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey, from consulting, deployment, and migration to cloud environment building and management. Its business comprises (i) digital transformation consulting services consisting of cloud suitability assessment, (ii) professional IT services comprising capabilities designed to facilitate seamless cloud integration and digital transformation, (iii) AI-powered proactive cloud managed services covering all aspects of day-to-day cloud maintenance and support, and (iv) IT infrastructure solutions covering on-premise private cloud setups and public cloud integrations, including infrastructure applications.
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.